Literature DB >> 24061636

Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis.

Yubin Liu1, Sujuan Kuang, Jun Zheng, Jianghua Zheng, Haosheng Jin, Sicong Chen, Zhixiang Jian.   

Abstract

Murine double minute 2 (MDM2) is a crucial negative regulator of p53 function through several mechanisms. There are many studies performed to assess the association between MDM2 rs2279744 polymorphism and hepatocellular carcinoma risk, but the impact of MDM2 rs2279744 polymorphism on hepatocellular carcinoma in East Asians is unclear owing to the inconsistent findings from previous studies. We conducted a comprehensive meta-analysis of epidemiological studies to shed some light on these contradicting results. We used pooled odds ratio (OR) with its 95 % confidence intervals (95 % CI) to assess the association. Overall, seven studies with a total of 4,993 subjects were finally included. The meta-analysis suggested that MDM2 rs2279744 polymorphism was significantly associated with increased risk of hepatocellular carcinoma in East Asians (G versus T: OR = 1.27, 95 % CI 1.06-1.52, P = 0.01; GG versus TT: OR = 1.59, 95 % CI 1.11-2.27, P = 0.01; GG/GT versus TT: OR = 1.41, 95 % CI 1.07-1.87, P = 0.02; GG versus TT/GT: OR = 1.32, 95 % CI 1.08-1.62, P = 0.008). Sensitivity analysis by excluding low-quality study still suggested that the association above was still significant. Thus, the findings from the meta-analysis support that MDM2 rs2279744 polymorphism is significantly associated with increased risk of hepatocellular carcinoma in East Asians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061636     DOI: 10.1007/s13277-013-1128-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

Review 1.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

2.  Major achievements in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 4.  P53 and prognosis: new insights and further complexity.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

5.  Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis.

Authors:  Bin Wang; Gang Huang; Dan Wang; Aijun Li; Zhipeng Xu; Ran Dong; Deqiang Zhang; Weiping Zhou
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

6.  MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population.

Authors:  Xi Wang; Xuelong Zhang; Bing Qiu; Yinhua Tang; He Sun; Hongfei Ji; Yan Liu; Lijun Shi; Guang Song; Youlin Yang
Journal:  Liver Int       Date:  2012-03-14       Impact factor: 5.828

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 8.  Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.

Authors:  A Lauria; M Tutone; M Ippolito; L Pantano; A M Almerico
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

9.  Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection.

Authors:  Y Ikeda; M Shimada; H Hasegawa; T Gion; K Kajiyama; K Shirabe; K Yanaga; K Takenaka; K Sugimachi
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

Review 10.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

View more
  1 in total

1.  Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma.

Authors:  Mei Liu; Su-jun Zheng; Yu Chen; Ning Li; Peng-fei Ren; Li-ping Dai; Zhong-ping Duan; Jian-Ying Zhang
Journal:  J Immunol Res       Date:  2014-05-14       Impact factor: 4.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.